X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/08/2859130/0/en/ORYZON-Announces-U-S-FDA-Clearance-of-CTEP-CRADA-Phase-I-II-Clinical-Trial-Sponsored-by-NCI-for-Iadademstat-Plus-Immune-Checkpoint-Inhibitors-in-1L-Extensive-Stage-Small-Cell-Lung-.html
https://www.globenewswire.com/news-release/2024/04/05/2858479/0/en/ORYZON-to-Provide-Corporate-Progress-Updates-at-Several-Events-in-April.html
https://www.globenewswire.com//news-release/2024/02/26/2835413/0/en/ORYZON-Reports-Financial-Results-and-Corporate-Update-for-Quarter-Ended-December-31-2023.html
https://www.globenewswire.com//news-release/2024/02/05/2823455/0/en/ORYZON-to-Provide-Corporate-Progress-Updates-at-Several-Events-in-February-March.html
https://www.globenewswire.com//news-release/2024/01/19/2812273/0/en/ORYZON-to-Host-KOL-Event-on-Phase-IIb-PORTICO-Topline-Study-Results-of-Vafidemstat-in-Borderline-Personality-Disorder-on-January-25-2024.html
https://www.fiercebiotech.com/biotech/oryzon-med-fails-improve-borderline-personality-disorder-executives-see-path-new-endpoints
https://www.globenewswire.com//news-release/2024/01/05/2804854/0/en/ORYZON-Announces-Topline-Results-from-Phase-IIb-PORTICO-Study-of-Vafidemstat-in-Borderline-Personality-Disorder-BPD.html
https://www.globenewswire.com//news-release/2024/01/03/2803220/0/en/ORYZON-to-Provide-Corporate-Progress-Updates-at-Several-Events-in-January.html
https://www.globenewswire.com//news-release/2023/12/04/2789939/0/en/ORYZON-Awarded-with-a-Grant-for-ORY-4001-From-the-ALS-Association-in-the-U-S.html
https://www.globenewswire.com//news-release/2023/11/21/2784308/0/en/ORYZON-Announces-a-New-Financing-Through-a-Convertible-Bond-Program-For-a-Total-Amount-of-Up-To-45-Million.html
Market Place
Share 
